ContraVir Appoints Industry Veteran William Hornung as Its Chief Financial Officer
Business Wire - Tue Jul 08, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that William Hornung has joined the Company as its Chief Financial Officer. Mr. Hornung has over 22 years of finance and operations leadership experience in the biopharmaceutical industry with companies such as PTC Therapeutics (NASDAQ
Baxter International to Split into Two Businesses; Spherix Sues Cisco over 11 Patent Infringements
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Baxter International Inc. (NYSE: BAX) - For an in-depth report on Baxter International Inc. follow: www.BullTrends.com/stockquote/BAX
ContraVir Appoints James Sapirstein as Chief Executive Officer and Board Member
Business Wire - Thu Mar 20, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development of antiviral technologies, today announced the appointment of James Sapirstein as Chief Executive Officer, and a member of the ContraVir Board of Directors. Mr. Sapirstein will lead the Company's strategic growth plan for the future, and, in particular, the clinical development of FV-100 to treat shingles (herpes zoster) patients.